National Research Corporation
NASDAQ:NRCMedical - Healthcare Information Services
+$0.07 today
- Market cap
- $555.16M
- Beta
- 0.40
- P/E (TTM)
- 43.0
- EPS (TTM)
- $0.41
- Dividend yield
- 3.14%
Volume 0.09M
Average 0.11M
NRC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
National Research CorporationNASDAQ: NRC
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $2.55M at the end of Q1 FY2026, up 1.8% from a year earlier and down 38.5% from the prior quarter. Over 3 fiscal years it compounded at -45.1% a year.
Context
- Cash & equivalents amounted to 1.9% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 4.14M USD
- Year-over-year change
- -2.2%
- 4-year CAGR
- -47.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.14M | -2.2% |
| FY2024 | 2024-12-31 | 4.23M | -36.4% |
| FY2023 | 2023-12-31 | 6.65M | -73.4% |
| FY2022 | 2022-12-31 | 25.03M | -54.0% |
| FY2021 | 2021-12-31 | 54.36M | — |
Cash & Equivalents vs competitors
How NRC compares with its peers on the latest reported figures
- NRC's Mar 2026 cash & equivalents of $2.55M is the lowest of the 8 companies compared; the peer median is $59.86M.
- Its year-over-year change of +1.8% is the 2nd highest of 8, against a peer median of -17.8%.
- Cash & equivalents amounts to 1.9% of total assets for NRC, versus a peer median of 11.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $157.65M | +48.6% | +3.7% | 30.6% | |
| Apr 2026 | $74.71M | -17.8% | -25.2% | 11.2% | |
| Mar 2026 | $65.39M | -4.6% | -24.2% | 41.7% | |
| Mar 2026 | $59.86M | -82.5% | -24.1% | 14.5% | |
| Mar 2026 | $48.71M | -37.0% | -7.7% | 9.2% | |
CTEVClaritev Corporation | Mar 2026 | $21.33M | -7.8% | -63.1% | 0.4% |
| Mar 2026 | $3.85M | -43.4% | -36.7% | 4.4% | |
| Mar 2026 | $2.55M | +1.8% | -45.1% | 1.9% | |
| Peer median (excluding NRC) | $59.86M | -17.8% | -24.2% | 11.2% | |
Competitors are the stored peer set for NRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.36M | 25.03M | 6.65M | 4.23M | 4.14M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 14.58M | 15.3M | 12.62M | 11.2M | 11.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 883K | 1.01M | 856K | 692K | 520K |
| Total Current Assets | 73.71M | 43.72M | 24.36M | 19.6M | 20.21M |
| Property, Plant & Equipment (Net) | 13.37M | 17.8M | 30.27M | 39.9M | 40.47M |
| Goodwill | 61.61M | 61.61M | 61.61M | 66.15M | 66.15M |
| Intangible Assets | 1.79M | 1.61M | 1.47M | 2.62M | 2.23M |
| Long-term Investments | 0 | 0 | 0 | 1.3M | 0 |
| Tax Assets | 14K | 14K | 0 | 0 | 0 |
| Other Non-current Assets | 7.05M | 5.7M | 4.73M | 2.98M | 5.82M |
| Total Non-current Assets | 83.83M | 86.75M | 98.08M | 112.94M | 114.67M |
| Total Assets | 157.54M | 130.46M | 122.44M | 132.54M | 134.88M |
| Account Payables | 1.94M | 1.15M | 1.3M | 1.19M | 4.07M |
| Short-term Debt | 5.24M | 5.32M | 7.82M | 4.79M | 4.01M |
| Tax Payables | 0 | 0 | 222K | 353K | 0 |
| Deferred Revenue | 17.21M | 15.2M | 14.83M | 15.79M | 16.2M |
| Other Current Liabilities | 8.85M | 7.19M | 8.08M | 541K | 5.12M |
| Total Current Liabilities | 40.39M | 33.42M | 36.2M | 35.86M | 36.62M |
| Long-term Debt | 22.27M | 17.69M | 29.47M | 57.9M | 75.02M |
| Deferred Tax Liabilities | 7M | 5.27M | 4.14M | 3.53M | 5.98M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 216K | 0 |
| Other Non-current Liabilities | 1.38M | 1.67M | 2M | 2.59M | 3.26M |
| Total Non-current Liabilities | 31.82M | 25.01M | 37.28M | 65.4M | 84.27M |
| Total Liabilities | 72.2M | 58.43M | 73.48M | 101.26M | 120.89M |
| Common Stock | 31K | 31K | 31K | 31K | 32K |
| Retained Earnings | (36.11M) | (25.18M) | (30.53M) | (17.06M) | (17.3M) |
| Accumulated OCI | (2.38M) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 85.34M | 72.03M | 48.96M | 31.28M | 13.99M |
| Total Debt | 28.68M | 23.39M | 38.96M | 64.41M | 79.04M |
| Net Debt | (25.68M) | (1.64M) | 32.3M | 60.18M | 74.9M |
National Research Corporation
NASDAQ:NRC
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.